1623. Antibiotic Utilization and Antimicrobial Stewardship in Community Hospitals
Session: Poster Abstract Session: Stewardship: Targets for Intervention
Friday, October 6, 2017
Room: Poster Hall CD
  • Abx Util Antimicrobial Stewardship in Community Hospitals Poster_ID Week 2017.pdf (271.1 kB)
  • Background:Overuse of antibiotics has been associated with the emergence of antibiotic resistance. This study aims to evaluate trends in antibiotic utilization as defined by days of therapy per 1000 patient days (DOT/1000 PD) in various community hospitals across the US.

    Methods: Eighteen network hospitals provided antibiotic utilization data (2012-2016) on overall antibiotic use and the following classes: narrow-spectrum β-lactams (ampicillin, nafcillin, oxacillin, cefazolin, and cephalexin), non-carbapenem antipseudomonal β-lactams (piperacillin/tazobactam, ceftazidime, and cefepime), carbapenems, anti-methicillin-resistant Staphylococcus aureus (MRSA) agents (vancomycin, linezolid, daptomycin, and tigecycline), and fluoroquinolones. Antibiotic utilization and change in utilization trend during the study period was calculated using linear regression (β coefficient).

    Results: Hospitals were primarily urban (72%) with an average of 209 total beds and 22 ICU beds. All hospitals have antimicrobial stewardship programs (ASPs) established during the study period. A decrease in antipseudomonal B-lactams and fluoroquinolones was observed during the study period, all other antibiotic classes had increased use (Table).

    Antibiotic Class

    Mean Utilization (Range), DOT/1000 PD

    Mean β Coefficient

    All Antibiotics

    62.3 (49.4-80.6)


    Narrow-spectrum β-lactams

    122.8 (64.5-207.2)


    Antipseudomonal β-lactams*

    129.6 (35-191.6)



    46.7 (145-82)



    156.9 (84.7-272.3)



    151.9 (88.5-207.6)


    *Excluding carbapenems


    Conclusion: Overall antibiotic utilization increased over five years, particularly carbapenems and anti-MRSA agents with the highest utilization being reported with the latter. Efforts are needed to halt or decrease the use of these broad spectrum antimicrobials.

    Abrar Thabit, PharmD, BCPS1,2, Katherine Shea, PharmD, BCPS AQ-ID3, Oscar Guzman, PharmD, BCPS3 and Kevin W. Garey, PharmD, M.S.4, (1)Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia, (2)Massachusetts General Hospital, Boston, MA, (3)Cardinal Health, Innovative Delivery Solutions, Houston, TX, (4)Pptr, University of Houston College of Pharmacy, Houston, TX


    A. Thabit, None

    K. Shea, None

    O. Guzman, None

    K. W. Garey, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.